Financial News · Live Terminal

Page 119 of 372

Opendoor Technologies to be Included in Russell 3000 Index

Opendoor Technologies (OPEN) said Wednesday that it will be included in the Russell 3000 Index as part of the 2026 annual reconstitution, effective after the market closes on June 26.The company said that inclusion in the Russell 3000 Index typically means membership in either the large-cap Russell 1000 Index or the small-cap Russell 2000 Index, as well as in relevant growth and value-style indexes.Price: $4.88, Change: $+0.40, Percent Change: +8.93%

$OPEN

Wire35d ago

Pacira BioSciences Says Exparel Linked to Lower Opioid Use, Healthcare Costs

Pacira BioSciences (PCRX) said Wednesday that a real-world study evaluating Exparel injectable suspension in total shoulder arthroplasty patients showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events.The study analyzed data from July 2019 to December 2024 from more than 6,400 opioid-naive Medicare Advantage patients undergoing outpatient total shoulder arthroplasty and compared outcomes between those given Exparel and those who received standard-of-care analgesia, the company said.Exparel, or bupivacaine liposome, is approved in the US for postsurgical pain management, the company said.Price: $24.43, Change: $+0.07, Percent Change: +0.27%

$PCRX

Wire35d ago

Market Chatter: Chevron Shareholders Reject Proposal for Appointing Independent Board Chair

Chevron (CVX) shareholders have rejected a proposal put forth at the company's annual general meeting that would have required appointing an independent board chair separate from the chief executive officer, Reuters reported Wednesday, citing preliminary voting results.Shareholders approved the appointment of all 12 nominees to the board and rejected two other shareholder proposals, the report stated.All voting results at the meeting were in line with what the company has recommended, according to the report.Chevron did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $181.36, Change: $-3.35, Percent Change: -1.81%

$CVX

Wire35d ago

Palvella Therapeutics Gets US Patent Supporting QTORIN Pitavastatin Through 2043

Palvella Therapeutics (PVLA) said Wednesday the United States Patent and Trademark Office has issued a patent, exclusively licensed from Yale University, supporting Palvella's QTORIN pitavastatin program for porokeratosis, including disseminated superficial actinic porokeratosis.QTORIN pitavastatin is an investigational topical therapy designed to enable pathogenesis-directed inhibition of the mevalonate pathway on-target and directly within affected skin tissue in porokeratosis, according to the company.The patent covers topical administration of HMG-CoA reductase inhibitors, including pitavastatin, for the treatment of porokeratosis, providing protection into 2043 for this pathogenesis-directed treatment approach, the company said.Palvella said it has also filed an additional patent application covering the QTORIN-derived formulation of pitavastatin and other statins and methods of use.Price: $116.72, Change: $-0.88, Percent Change: -0.74%

$PVLA

Wire35d ago

Energy Vault Completes Acquisition of 850 MW Japan Energy Storage Portfolio From BayWa

Energy Vault (NRGV) said Wednesday it completed its acquisition of an 850 megawatt battery energy storage system development portfolio in Japan from BayWa.The deal provides Energy Vault with an in-country platform, a project pipeline, and a local development team, the company said.The portfolio includes about 350 megawatts of advanced-stage battery energy storage system projects expected to reach notice to proceed in the second half of 2027, with commercial operation dates expected to begin in mid-2028.Additionally, 500 megawatts of early-stage projects provide a multi-year development runway, the company said.Price: $5.33, Change: $+0.08, Percent Change: +1.52%

$NRGV

Wire35d ago

Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease

Altimmune (ALT) said Wednesday that data from the phase 2b trial of pemvidutide to treat liver disease demonstrated improvements across non-invasive tests of metabolic dysfunction-associated steatohepatitis activity and fibrosis at 24 weeks compared with placebo.AI-based pathology showed that pemvidutide treatment led to considerable reductions in fibrosis values compared with placebo, according to a statement.The company will start patient enrollment for its phase 3 trial of the drug in H2 based on the latest phase 2b results, according to the company.Price: $2.99, Change: $+0.06, Percent Change: +2.05%

$ALT

Wire35d ago

Abacus Global Management, Manning & Napier Form Strategic Alliance

Abacus Global Management (ABX) and Manning & Napier said Wednesday they have entered a strategic alliance agreement and announced the closing of Abacus's minority equity investment of about $53 million in Manning & Napier.The companies said the partnership aims to create value in three core areas, including lead generation and referrals, product development and distribution, and joint client solutions.The agreement allows both companies to collaborate more closely by combining Abacus's longevity data and actuarial expertise with Manning & Napier's investment management and financial planning capabilities, the companies added.Price: $9.58, Change: $+0.02, Percent Change: +0.21%

$ABX

Wire35d ago

Veeva Says Teva Pharmaceutical, Merck KGaA Select its Vault CRM

Veeva Systems (VEEV) said Wednesday that Teva Pharmaceutical (TEVA) and Germany-based Merck KGaA have committed to use its Vault CRM software globally.Vault CRM is an application for life sciences companies that connects sales, marketing, and medical teams on a single platform, Veeva said.Financial terms of the agreements were not disclosed.Shares of Veeva were up by more than 3% in Wednesday trading.Price: $163.01, Change: $+4.47, Percent Change: +2.82%

$TEVA$VEEV

Wire35d ago

Abbott Gets CE Mark for Glucose-Ketone Sensing Technology for Diabetes

Abbott (ABT) said Wednesday it has secured the CE Mark for its dual glucose-ketone sensing technology for people with diabetes.The systems, branded as Libre Duo and Libre Duo 10 Day, are designed to continuously measure glucose and ketone levels every minute, the company said.Abbott said it plans to start launching Libre Duo systems in some European countries later this year.Price: $86.44, Change: $-0.23, Percent Change: -0.27%

$ABT

Wire35d ago

Roku Introduces New TV Home Screen

Roku (ROKU) said Wednesday it is rolling out a new Home Screen that enables "less time searching and more time streaming."The new Roku Home Screen recommends content based on the viewers' interests using intelligence models, the company said.Roku said the new Home Screen will be initially rolled out across all Roku TVs and streaming devices in the US and is expected to reach over 100 million streaming households soon.Roku shares were up 2.5% in Wednesday trading.Price: $130.78, Change: $+3.17, Percent Change: +2.48%

$ROKU

Wire35d ago

Corcept Therapeutics to Resubmit New Drug Application for Relacorilant to Treat Cushing's Syndrome

Corcept Therapeutics (CORT) said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.The company said it will resubmit the NDA based on positive outcomes of additional analyses of the application data, which were conducted following issuance of a complete response letter.The FDA notified the company to expect a Prescription Drug User Fee Act date six months following the application submission, according to a statement.Price: $64.86, Change: $+4.50, Percent Change: +7.46%

$CORT

Wire35d ago

Ingredion Says 96% of its Tier 1 Priority Crops Are Now Sustainably Sourced

Ingredion (INGR) said Wednesday that more than 96% of its tier 1 priority crops are now sustainably sourced, up from 25% five years ago.Ingredion also said it has diverted about 95% of total waste from landfills and has achieved zero waste to landfills, defined as less than 0.5% of the plant's solid waste going to landfill or waste incineration without energy recovery, at 16 manufacturing facilities.Shares of the company were up 1.7% in Wednesday trading.Price: $104.44, Change: $+1.14, Percent Change: +1.10%

$INGR

Wire35d ago

Macquarie Adjusts Price Target on Zscaler to $172 From $210, Maintains Outperform Rating

Zscaler (ZS) has an average rating of buy and mean price target of $199.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $127.46, Change: $-57.15, Percent Change: -30.96%

$ZS

Wire35d ago

Tigress Financial Raises Nvidia Price Target to $425 From $360, Maintains Strong Buy Rating

Nvidia (NVDA) has an average rating of Buy and mean price target of $305.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $210.39, Change: $-4.47, Percent Change: -2.08%

$NVDA

Wire35d ago

Climb Enters North American Distribution Partnership With Quantum

Climb Global Solutions' (CLMB) Climb subsidiary said Wednesday that it has entered into a distribution partnership for North America with Quantum (QMCO).The partnership will broaden access to Quantum's full product portfolio, Climb said.Financial terms of the partnership were not provided.Shares of Climb were up 2.3% in Wednesday trading, while Quantum stock was down 1.4%.Price: $21.71, Change: $+0.49, Percent Change: +2.31%

$CLMB$QMCO

Wire35d ago

GoodRx Launches New Monthly Subscription GoodRx Companion

GoodRx (GDRX) said Wednesday it launched GoodRx Companion, a $14.99-a-month subscription that provides access to generic medications, online care visits, and other healthcare services.The company said the new product expands its subscription strategy as clients are facing tighter insurance restrictions and rising out-of-pocket healthcare costs.Price: $2.82, Change: $+0.04, Percent Change: +1.26%

$GDRX

Wire35d ago

IQIYI's Nadou Pro AI Film, TV Production Platform Surpasses 10,000-Creator Mark

IQIYI (IQ) said in a Wednesday release that its Nadou Pro AI professional film and television production platform has onboarded over 10,000 active creators in less than one month.The platform, which was launched commercially on April 20, has supported more than 100 iQIYI original productions to date, the company said.Price: $1.09, Change: $-0.01, Percent Change: -0.91%

$IQ

Wire35d ago

BofA Securities Adjusts Twilio Price Target to $235 From $225, Maintains Buy Rating

Twilio (TWLO) has an average rating of overweight and mean price target of $201.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $189.67, Change: $+0.02, Percent Change: +0.01%

$TWLO

Wire35d ago

Veeva Systems Launching Agentic Platform for Drug Development Projects

Veeva Systems (VEEV) said Wednesday it is launching Falcon, an agentic platform to support drug development projects.Falcon is designed to integrate with Veeva's clinical, regulatory, and safety applications to cut costs and maintain compliance for biopharma clients, the company said.Early adopter availability is expected in November, Veeva said.Veeva shares were 2% higher in Wednesday trading.Price: $159.08, Change: $+0.58, Percent Change: +0.37%

$VEEV

Wire35d ago

Astrotech Shares Surge After Board Approves Initiative to Advance Quantum Computing Manufacturing

Astrotech (ASTC) shares were up 190% in Wednesday trading after the company's board approved a strategic initiative aimed at evaluating emerging opportunities associated with Moon-based quantum computing manufacturing.The initiative will focus on lunar resource development, autonomous lunar industrial infrastructure, and future Moon-based advanced computing and semiconductor manufacturing opportunities, the company said.The emerging opportunities include NASA's Artemis Program and the Commercial Lunar Payload Services program, Astrotech said.Price: $7.21, Change: $+4.74, Percent Change: +191.70%

$ASTC

Showing 2361-2380 of 7433